Anlon Healthcare Limited share price
Anlon Healthcare Limited manufactures and sells active pharmaceutical ingredients in India and internationally. The company also offers bulk drugs; advanced pharmaceutical intermediates; nutraceutical API products; and drug intermediates. It also manufactures loxoprofen sodium dihydrate, ketoprofen, and dexketoprofen trometamol products for pain management and anti-inflammatory therapies. Anlon Healthcare Limited was incorporated in 2013 and is based in Rajkot, India.Read more
- Market Cap₹ 1,427 Cr.
- Current Price₹ 26.85
- High / Low₹ 37 / 10
- Stock P/E39.5
- Book Value₹ 5
- Dividend Yield0.00 %
- ROCE17.0 %
- ROE18.40 %
- Face Value₹ 2.0
More figures (10)
- EPS (TTM)₹ 0.68
- Price / Book5.25
- OPM26.9 %
- Debt / Equity0.19
- Sales growth (4Y)15.1 %
- Profit growth (4Y)69.8 %
- Promoter holding73.3 %
- EV / EBITDA21.0
- Beta—
- All-time high₹ 37
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| AHCL | +33.98% | +76.88% | +90.12% | +77.87% | +116.90% | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Anlon Healthcare Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,427 crore.
- It trades at 39.5 times its last 12 months' earnings and 5.3 times book value.
- Revenue grew 15.1% a year over the last 4 years, profit 69.8% a year.
- Return on equity was 18.4% and return on capital employed 17.0% in the latest year.
- Debt was 0.19 times shareholders' equity.
- The share price is 27.9% below its 52-week high and up 116.9% over one year.
- Promoters and insiders hold about 73.3%; institutions about 0.0%.
Pros
AI- Strong return on equity: 42.3% on average over the last 3 years.
- Borrowings are moderate at 0.19 times shareholders' equity.
Cons
AI- The company has not paid a dividend recently.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Anlon Healthcare Limited
Anlon Healthcare Limited manufactures and sells active pharmaceutical ingredients in India and internationally. The company also offers bulk drugs; advanced pharmaceutical intermediates; nutraceutical API products; and drug intermediates. It also manufactures loxoprofen sodium dihydrate, ketoprofen, and dexketoprofen trometamol products for pain management and anti-inflammatory therapies. Anlon Healthcare Limited was incorporated in 2013 and is based in Rajkot, India.
- Employees
- 119
- Head office
- Rajkot
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Anlon Healthcare | 26.85 | 39.5 | 1,427 | 0.00 | 8 | — | 88 | — | 17.0 | 18.4 | 5.25 | 26.9 | 0.19 | 73.27 | 172 | 15.1 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,921 | 54.85 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,980 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 786 | -39.18 | 7,119 | 2.33 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 28,163 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 574 | 29.12 | 4,031 | 12.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 54 Co. | 1,712.85 | 32.9 | 14,866 | 0.27 | 680 | 14.29 | 6,020 | 18.48 | 16.0 | 13.8 | 4.02 | 15.7 | 0.21 | 55.20 | 20,499 | 11.0 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own past sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2026 |
|---|---|
| Sales | 172 |
| 124 | |
| Material Cost % | 61% |
| Employee Cost % | 3% |
| Other Expenses % | 8% |
| Operating Profit | 48 |
| OPM % | 28% |
| Other Income | 0 |
| Interest | 4 |
| Depreciation | 2 |
| Profit before tax | 43 |
| 32% | |
| Current tax | 12 |
| Deferred tax | 2 |
| 29 | |
| Minority share | 1 |
| Profit to shareholders | 29 |
| EPS in Rs | 0.61 |
Stock Price CAGR
- 1 Year:
- 117%
Return on Equity
- 4 Years:
- 51%
- Last Year:
- 18%
| ₹ Cr | Mar 2026 | TTM |
|---|---|---|
| Sales | 176 | 174 |
| 130 | 127 | |
| Material Cost % | 64% | 62% |
| Employee Cost % | 3% | 3% |
| Other Expenses % | 7% | 8% |
| Operating Profit | 46 | 47 |
| OPM % | 26% | 27% |
| Other Income | 0 | 0 |
| Interest | 4 | 5 |
| Depreciation | 1 | 2 |
| Profit before tax | 41 | 42 |
| 32% | 30% | |
| Current tax | 11 | |
| Deferred tax | 1 | |
| Net Profit | 28 | 29 |
| EPS in Rs | 0.59 | 0.64 |
Compounded Sales Growth
- TTM:
- -1%
Compounded Profit Growth
- TTM:
- 4%
Stock Price CAGR
- 1 Year:
- 117%
Return on Equity
- 4 Years:
- 51%
- Last Year:
- 18%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 12 | 16 | 40 | 53 |
| Reserves | -5 | 5 | 41 | 177 |
| 70 | 81 | 67 | 44 | |
| Long term borrowings | 58 | 54 | 38 | 6 |
| Short term borrowings | 12 | 27 | 28 | 38 |
| 34 | 26 | 34 | 100 | |
| Trade payables | 25 | 20 | 20 | 42 |
| Minority interest | 25 | |||
| Current liabilities | 44 | 50 | 60 | 108 |
| Total Liabilities | 112 | 128 | 181 | 374 |
| 26 | 27 | 23 | 47 | |
| Gross block | 35 | 38 | 36 | 61 |
| Accumulated depreciation | 9 | 11 | 13 | 14 |
| Goodwill & intangibles | 0 | |||
| CWIP | 7 | |||
| 86 | 101 | 158 | 321 | |
| Inventories | 27 | 42 | 50 | 113 |
| Trade receivables | 44 | 39 | 75 | 104 |
| Cash & equivalents | 1 | 2 | 1 | 4 |
| Current assets | 86 | 101 | 158 | 308 |
| Total Assets | 112 | 128 | 181 | 374 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| -3 | -3 | -23 | -79 | |
| Profit for the year | 6 | 10 | 21 | 29 |
| Working capital changes | -15 | -19 | -54 | -122 |
| Direct taxes paid | -0 | 5 | -5 | |
| -0 | -3 | 3 | -36 | |
| Fixed assets purchased | -0 | -4 | -1 | -36 |
| Fixed assets sold | 0 | 3 | ||
| Investments purchased | -0 | |||
| 2 | 8 | 19 | 119 | |
| Proceeds from borrowings | 6 | 9 | ||
| Repayment of borrowings | -4 | -16 | -32 | |
| Interest paid | -4 | -4 | -4 | -4 |
| Net Cash Flow | -1 | 2 | -1 | 3 |
| Free Cash Flow | -3 | -7 | -23 | -116 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 78.9% | 68.0% | 40.4% | 18.4% |
| ROCE | — | 15.9% | 17.8% | 25.0% | 17.0% |
| Operating margin | — | 9.8% | 20.8% | 25.4% | 26.9% |
| Net margin | — | 5.2% | 14.5% | 17.1% | 16.6% |
| Debt / equity | — | 9.54 | 3.86 | 0.83 | 0.19 |
| Current ratio | — | 1.97 | 2.01 | 2.64 | 2.87 |
| Debtor days | — | 142 | 212 | 228 | 220 |
| Inventory days | — | 111 | 418 | 243 | 384 |
| Days payable | — | 105 | 200 | 95 | 143 |
| Cash conversion cycle | — | 148 | 430 | 376 | 461 |
| Working capital days | — | 137 | 277 | 299 | 426 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 52.68%
- FIIs 1.67%
- DIIs 1.22%
- Public 44.43%
| % | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Promoters | 52.68% | 52.68% | 52.68% | 52.68% |
| 0.23% | 0.32% | 1.67% | ||
| Foreign portfolio investors (Cat. I) | 0.23% | 0.30% | 0.77% | |
| Foreign portfolio investors (Cat. II) | 0.02% | 0.90% | ||
| 2.83% | 4.49% | 4.60% | 1.22% | |
| Insurance companies | 0.31% | 0.09% | 0.06% | 0.06% |
| Alternative investment funds | 2.52% | 4.40% | 4.54% | 1.17% |
| 44.49% | 42.60% | 42.40% | 44.43% | |
| Retail (up to ₹2 lakh) | 7.13% | 7.97% | 8.95% | 11.69% |
| HNIs (above ₹2 lakh) | 13.60% | 15.61% | 15.43% | 14.50% |
| NRIs | 0.32% | 0.34% | 0.34% | 0.47% |
| Bodies corporate | 22.84% | 17.69% | 16.76% | 16.73% |
| No. of Shareholders | 12,464 | 11,412 | 12,484 | 34,671 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Documents
Announcements
- Outcome of Board MeetingAnlon Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on October 13, 2026.13-Oct-2026
- Trading WindowAnlon Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201528-Sep-2026
- General UpdatesAnlon Healthcare Limited has informed the Exchange about General Updates24-Sep-2026
- Disclosure of material issueAnlon Healthcare Limited has informed regarding Disclosure of material issue21-Sep-2026
- Disclosure of material issueAnlon Healthcare Limited has informed regarding Disclosure of material issue21-Sep-2026
- Price movementSignificant movement in price has been observed in Anlon Healthcare Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and…17-Sep-2026
- Shareholders meetingAnlon Healthcare Limited has informed the Exchange regarding Revised Proceedings of Annual General Meeting held on September 05, 202607-Sep-2026
- Shareholders meetingAnlon Healthcare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 05, 2026. Further, the company has informed the Exchange …05-Sep-2026
- Shareholders meetingAnlon Healthcare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 05, 202605-Sep-2026
- CorrigendumAnlon Healthcare Limited has informed the Exchange regarding Corrigendum to Notice of Annual General Meeting to be held on September 05, 202625-Aug-2026
- Copy of Newspaper PublicationAnlon Healthcare Limited has informed the Exchange about Copy of Newspaper Publication17-Aug-2026
- Shareholders meetingAnlon Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 05, 202614-Aug-2026
Annual reports
Credit ratings
Concalls & investor meets
- Analysts/Institutional Investor Meet/Con. Call UpdatesAnlon Healthcare Limited has informed the Exchange about Transcript12-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAnlon Healthcare Limited has informed the Exchange about Link of Recording06-Aug-2026
- Investor PresentationAnlon Healthcare Limited has informed the Exchange about Investor Presentation05-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAnlon Healthcare Limited has informed the Exchange about Schedule of meet31-Jul-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAnlon Healthcare Limited has informed the Exchange about Transcript09-Jun-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAnlon Healthcare Limited has informed the Exchange about Link of Recording03-Jun-2026
- Investor PresentationAnlon Healthcare Limited has informed the Exchange about Investor Presentation03-Jun-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAnlon Healthcare Limited has informed the Exchange about Schedule of meet28-May-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAnlon Healthcare Limited has informed the Exchange about Schedule of meet18-Mar-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesAnlon Healthcare Limited has informed the Exchange about Transcript24-Feb-2026
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 1 Jan 1970
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
- Outcome of Board MeetingAnlon Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on October 13, 2026.NSE filing · 13-Oct-2026
- Trading WindowAnlon Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 28-Sep-2026
- General UpdatesAnlon Healthcare Limited has informed the Exchange about General UpdatesNSE filing · 24-Sep-2026
- Disclosure of material issueAnlon Healthcare Limited has informed regarding Disclosure of material issueNSE filing · 21-Sep-2026
- Disclosure of material issueAnlon Healthcare Limited has informed regarding Disclosure of material issueNSE filing · 21-Sep-2026
- Price movementSignificant movement in price has been observed in Anlon Healthcare Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and…NSE filing · 17-Sep-2026
- Shareholders meetingAnlon Healthcare Limited has informed the Exchange regarding Revised Proceedings of Annual General Meeting held on September 05, 2026NSE filing · 07-Sep-2026
- Shareholders meetingAnlon Healthcare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 05, 2026. Further, the company has informed the Exchange …NSE filing · 05-Sep-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Anlon Healthcare Limited
What is the share price of Anlon Healthcare Limited today?
What is the market cap of Anlon Healthcare Limited?
What is the P/E ratio of Anlon Healthcare Limited?
Is Anlon Healthcare Limited a good investment?
How can I buy Anlon Healthcare Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.